Miller Anestesia

patients undergoing cardiac surgery by heparin

dosing based on heparin blood concentrations

rather than ACT. Thromb Haemost 76:902–908,

1996.

117. Gravlee GP, Haddon WS, Rothberger HK, et al:

Heparin dosing and monitoring for cardiopulmo-

nary bypass: A comparison of techniques with mea-

surement of subclinical plasma coagulation. J

Thorac Cardiovasc Surg 99:518–527, 1990.

118. Wang JS, Lin CY, Karp RB: Comparison of high-

dose thrombin time with activated clotting time for

monitoring of anticoagulant effects of heparin in

cardiac surgical patients. Anesth Analg 79:9–13,

1994.

119. Shore-Lesserson L, Manspeizer HE, Bolastig M, et

al: Anticoagulation for cardiac surgery in patients

receiving preoperative heparin: use of the high-dose

thrombin time. Anesth Analg 90:813–818, 2000.

120. Tabuchi N, Njo TL, Tigchelaar I, et al: Monitoring

of anticoagulation in aprotinin-treated patients

during heart operation. Ann Thorac Surg 58:774–

777, 1994.

121. Gravlee GP, Rogers AT, Dudas LM, et al: Heparin

management protocol for cardiopulmonary bypass

influences postoperative heparin rebound but not

bleeding. Anesthesiology 76:393–401, 1992.

122. Kottke-Marchant K, Sapatnekar S: Hemostatic

abnormalities in cardiopulmonary bypass: Patho-

physiologic and transfusion considerations. Semin

Cardiothorac Vasc Anesth 5:187–206, 2001.

123. Boyle EM Jr, Verrier ED, Spiess BD: Endothelial cell

injury in cardiovascular surgery: The procoagulant

response. Ann Thorac Surg 62:1549–1557, 1996.

124. Boisclair MD, Lane DA, Philippou H, et al: Mecha-

nisms of thrombin generation during surgery and

cardiopulmonary bypass. Blood 82:3350–3357,

1993.

125. Burman JF, Chung HI, Lane DA, et al: Role of factor

XII in thrombin generation and fibrinolysis during

cardiopulmonary bypass. Lancet 344:1192–1193,

1994.

126. Edmunds LH Jr, Colman RW: Thrombin during

cardiopulmonary bypass. Ann Thorac Surg

82:2315–2322, 2006.

127. Edmunds LH, Jr: Inflammatory response to cardio-

pulmonary bypass. Ann Thorac Surg 66:S12–S16,

1998.

128. Collen D: The plasminogen (fibrinolytic) system.

Thromb Haemost 82:259–270, 1999.

129. Spiess BD, Horrow J, Kaplan JA: Transfusion medi-

cine and coagulation disorders. In Kaplan JA, Reich

DL, Lake CL, et al (eds): Kaplan’s Cardiac Anesthe-

sia, 5th ed. Philadelphia, Elsevier Saunders, 2006, pp

937–985.

130. Linden MD, Schneider M, Baker S, et al: Decreased

concentration of antithrombin after preoperative

therapeutic heparin does not cause heparin resis-

tance during cardiopulmonary bypass. J Cardiotho-

rac Vasc Anesth 18:131–135, 2004.

131. Ranucci M, Isgro G, Cazzaniga A, et al: Predictors

for heparin resistance in patients undergoing coro-

nary artery bypass grafting. Perfusion 14:437–442,

1999.

132. Ranucci M, Isgro G, Cazzaniga A, et al: Different

patterns of heparin resistance: Therapeutic implica-

tions. Perfusion 17:199–204, 2002.

133. Avidan MS, Levy JH, Scholz J, et al: A phase III,

double-blind, placebo-controlled, multicenter study

on the efficacy of recombinant human antithrom-

bin in heparin-resistant patients scheduled to

undergo cardiac surgery necessitating cardiopul-

monary bypass. Anesthesiology 102:276–284, 2005.

134. Lemmer JH Jr, Despotis GJ: Antithrombin III con-

centrate to treat heparin resistance in patients

undergoing cardiac surgery. J Thorac Cardiovasc

Surg 123:213–217, 2002.

135. Everett BM, Yeh R, Foo SY, et al: Prevalence of

heparin/platelet factor 4 antibodies before and after

cardiac surgery. Ann Thorac Surg 83:592–597, 2007.

136. Bauer TL, Arepally G, Konkle BA, et al: Prevalence

of heparin-associated antibodies without thrombo-

sis in patients undergoing cardiopulmonary bypass

surgery. Circulation 95:1242–1246, 1997.

137. Warkentin TE, Greinacher A: Heparin-induced

thrombocytopenia and cardiac surgery. AnnThorac

Surg 76:2121–2131, 2003.

138. Murphy GS, Marymont JH: Alternative anticoagu-

lation management strategies for the patient with

heparin-induced thrombocytopenia undergoing

cardiac surgery. J Cardiothorac Vasc Anesth

21:113–126, 2007.

139. Koster A, Dyke CM, Aldea G, et al: Bivalirudin

during cardiopulmonary bypass in patients with

previous or acute heparin-induced thrombocytope-

nia and heparin antibodies: Results of the CHOO-

SE-ON trial. Ann Thorac Surg 83:572–577, 2007.

140. Koster A, Spiess B, Jurmann M, et al: Bivalirudin

provides rapid, effective, and reliable anticoagula-

tion during off-pump coronary revascularization:

Results of the “EVOLUTION OFF” trial. Anesth

Analg 103:540–544, 2006.

141. Dyke CM, Smedira NG, Koster A, et al: A compari-

son of bivalirudin to heparin with protamine rever-

sal in patients undergoing cardiac surgery with

cardiopulmonary bypass: The EVOLUTION-ON

study. J Thorac Cardiovasc Surg 131:533–539,

2006.

142. Jobes DR: Safety issues in heparin and protamine

administration for extracorporeal circulation. J

Cardiothorac Vasc Anesth 12:17–20, 1998.

143. Kimmel SE, Sekeres M, Berlin JA, et al: Mortality

and adverse events after protamine administration

in patients undergoing cardiopulmonary bypass.

Anesth Analg 94:1402–1408, 2002.

144. Welsby IJ, Newman MF, Phillips-Bute B, et al:

Hemodynamic changes after protamine adminis-

tration: Association with mortality after coronary

artery bypass surgery. Anesthesiology 102:308–314,

2005.

145. Gottschlich GM, Gravlee GP, Georgitis JW: Adverse

reactions to protamine sulfate during cardiac

surgery in diabetic and non-diabetic patients. Ann

Allergy 61:277–281, 1988.

146. Raikar GV, Hisamochi K, Raikar BL, et al: Nitric

oxide inhibition attenuates systemic hypotension

produced by protamine. J Thorac Cardiovasc Surg

111:1240–1246, 1996.

147. Adourian UA, Hirshman CA, Adkinson NF Jr, et al:

Immunoreactivity of protamine preparations used

to reverse heparin anticoagulation. Anesthesiology

73:328–331, 1990.

148. Weiler JM, Gellhaus MA, Carter JG, et al: A pros-

pective study of the risk of an immediate adverse

reaction to protamine sulfate during cardiopulmo-

nary bypass surgery. J Allergy Clin Immunol

85:713–719, 1990.

149. Weiss ME, Nyhan D, Peng ZK, et al: Association of

protamine IgE and IgG antibodies with life-threate-

ning reactions to intravenous protamine. N Engl J

Med 320:886–892, 1989.

150. Kimmel SE, Sekeres MA, Berlin JA, et al: Risk

factors for clinically important adverse events after

protamine administration following cardiopulmo-

nary bypass. J Am Coll Cardiol 32:1916–1922,

1998.

151. Comunale ME, Maslow A, Robertson LK, et al:

Effect of site of venous protamine administration,

previously alleged risk factors, and preoperative use

of aspirin on acute protamine-induced pulmonary

vasoconstriction. J Cardiothorac Vasc Anesth

17:309–313, 2003.

152. Montalescot G, Lowenstein E, Ogletree ML, et al:

Thromboxane receptor blockade prevents pulmo-

nary hypertension induced by heparin-protamine

reactions in awake sheep. Circulation 82:1765–1777,

1990.

153. Kanbak M, Kahraman S, Celebioglu B, et al: Pro-

phylactic administration of histamine 1and/or his-

tamine 2 receptor blockers in the prevention of

heparin- and protamine-related haemodynamic

effects. Anaesth Intensive Care 24:559–563, 1996.

154. Donahue BS: Factor V Leiden and perioperative

risk. Anesth Analg 98:1623–1634, 2004.

155. Sweeney JD, Blair AJ, Dupuis MP, et al: Aprotinin,

cardiac surgery, and factor V Leiden. Transfusion

(Paris) 37:1173–1178, 1997.

156. Shore-Lesserson L, Reich DL: A case of severe

diffuse venous thromboembolism associated with

aprotinin and hypothermic circulatory arrest in a

cardiac surgical patient with factor V Leiden. Anes-

thesiology 105:219–221, 2006.

157. Fanashawe MP, Shore-Lesserson L, Reich DL: Two

cases of fatal thrombosis after aminocaproic acid

therapy and deep hypothermic circulatory arrest.

Anesthesiology 95:1525–1527, 2001.

158. Moor E, Silveira A, van’t Hooft F, et al: Coagulation

factor V (Arg506

→

Gln) mutation and early saphe-

nous vein graft occlusion after coronary artery bypass

grafting. Thromb Haemost 80:220–224, 1998.

159. Crowther MA, Kelton JG: Congenital thrombophi-

lic states associated with venous thrombosis: A qua-

litative overview and proposed classification system.

Ann Intern Med 138:128–134, 2003.

160. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al:

ACC/AHA/SCAI 2005 guideline update for percu-

taneous coronary intervention—summary article:

A Report of the American College of Cardiology/

American Heart Association Task Force on Practice

Guidelines (ACC/AHA/SCAI Writing Committee

to Update the 2001 Guidelines for Percutaneous

Coronary Intervention). J Am Coll Cardiol 47:216–

235, 2006.

161. Taggart DP, Siddiqui A, Wheatley DJ: Low-dose

preoperative aspirin therapy, postoperative blood

loss, and transfusion requirements. Ann Thorac

Surg 50:424–428, 1990.

162. Bashein G, Nessly ML, Rice AL, et al: Preoperative

aspirin therapy and reoperation for bleeding after

coronary artery bypass surgery. Arch Intern Med

151:89–93, 1991.

163. Reich DL, Patel GC, Vela-Cantos F, et al: Aspirin

does not increase homologous blood requirements

in elective coronary bypass surgery. Anesth Analg

79:4–8, 1994.

164. Tuman KJ, McCarthy RJ, O’Connor CJ, et al:

Aspirin does not increase allogeneic blood transfu-

sion in reoperative coronary artery surgery. Anesth

Analg 83:1178–1184, 1996.

165. Hongo RH, Ley J, Dick SE, et al: The effect of clopi-

dogrel in combination with aspirin when given

before coronary artery bypass grafting. J Am Coll

Cardiol 40:231–237, 2002.

166. Chen L, Bracey AW, Radovancevic R, et al: Clopido-

grel and bleeding in patients undergoing elective

coronary artery bypass grafting. J Thorac Cardio-

vasc Surg 128:425–431, 2004.

167. von Heymann C, Redlich U, Moritz M, et al: Aspirin

and clopidogrel taken until 2 days prior to coronary

artery bypass graft surgery is associated with

increased postoperative drainage loss. Thorac Car-

diovasc Surg 53:341–345, 2005.

168. Pothula S, Sanchala VT, Nagappala B, et al: The

effect of preoperative antiplatelet/anticoagulant

prophylaxis on postoperative blood loss in cardiac

surgery. Anesth Analg 98:4–10, 2004.

169. Ascione R, Ghosh A, Rogers CA, et al: In-hospital

patients exposed to clopidogrel before coronary

artery bypass graft surgery: A word of caution. Ann

Thorac Surg 79:1210–1216, 2005.

170. Kapetanakis EI, Medlam DA, Boyce SW, et al: Clo-

pidogrel administration prior to coronary artery

bypass grafting surgery: The cardiologist’s panacea

or the surgeon’s headache? Eur Heart J 26:576–583,

2005.

171. Chu MW, Wilson SR, Novick RJ, et al: Does clopi-

dogrel increase blood loss following coronary artery

bypass surgery? Ann Thorac Surg 78:1536–1541,

2004.

172. Kapetanakis EI, Medlam DA, Petro KR, et al: Effect

of clopidogrel premedication in off-pump cardiac

surgery: Are we forfeiting the benefits of reduced

hemorrhagic sequelae? Circulation 113:1667–1674,

2006.

173. Karabulut H, Toraman F, Evrenkaya S, et al: Clopi-

dogrel does not increase bleeding and allogenic

blood transfusion in coronary artery surgery. Eur J

Cardiothorac Surg 25:419–423, 2004.

174. Lincoff AM, LeNarz LA, Despotis GJ, et al: Abcixi-

mab and bleeding during coronary surgery: Results

1734

Anestesia por subespecialidades en el adulto